There are 2789 resources available
1668TiP - Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
Presenter: Afshin Dowlati
Session: ePoster Display
1673P - Efficacy and safety of 5 mg olanzapine for the prevention of carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II study
Presenter: Yukiyoshi Fujita
Session: ePoster Display
1553TiP - A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma
Presenter: Christoph Schliemann
Session: ePoster Display
1555TiP - A phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS): The PULSAR trial
Presenter: Alice Indini
Session: ePoster Display
1568P - Clinical and laboratory outcomes of solid cancer patients reinfected with SARS-CoV-2
Presenter: Ozan Yazıcı
Session: ePoster Display
1569P - A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis
Presenter: Maria Sereno Moyano
Session: ePoster Display
1570P - Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
Presenter: Markus Joerger
Session: ePoster Display
1571P - COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium
Presenter: Julian Hong
Session: ePoster Display